Eli Lilly and Company (NYSE:LLY) is Wahed Invest LLC’s 8th Largest Position

Wahed Invest LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 7.2% during the fourth quarter, Holdings Channel reports. The firm owned 14,429 shares of the company’s stock after buying an additional 964 shares during the quarter. Eli Lilly and Company comprises approximately 2.2% of Wahed Invest LLC’s holdings, making the stock its 8th biggest position. Wahed Invest LLC’s holdings in Eli Lilly and Company were worth $8,411,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC purchased a new stake in Eli Lilly and Company in the 3rd quarter valued at approximately $234,000. Loomis Sayles & Co. L P raised its holdings in shares of Eli Lilly and Company by 324.2% in the third quarter. Loomis Sayles & Co. L P now owns 1,069 shares of the company’s stock worth $574,000 after acquiring an additional 817 shares during the last quarter. Financial Engines Advisors L.L.C. lifted its position in shares of Eli Lilly and Company by 23.6% in the third quarter. Financial Engines Advisors L.L.C. now owns 1,038 shares of the company’s stock valued at $557,000 after acquiring an additional 198 shares in the last quarter. Envestnet Portfolio Solutions Inc. acquired a new stake in shares of Eli Lilly and Company during the third quarter valued at $14,847,000. Finally, Envestnet Asset Management Inc. increased its position in Eli Lilly and Company by 22.7% during the 3rd quarter. Envestnet Asset Management Inc. now owns 805,487 shares of the company’s stock worth $432,651,000 after purchasing an additional 149,183 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $885.01 on Tuesday. The company has a market cap of $841.12 billion, a price-to-earnings ratio of 130.34, a price-to-earnings-growth ratio of 1.92 and a beta of 0.36. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $892.20. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The stock’s 50-day moving average is $788.10 and its 200-day moving average is $721.39.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.62 earnings per share. Equities analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 10th. Investors of record on Thursday, May 16th were issued a dividend of $1.30 per share. The ex-dividend date was Wednesday, May 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.59%. Eli Lilly and Company’s payout ratio is 76.58%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on LLY. Jefferies Financial Group upped their target price on shares of Eli Lilly and Company from $925.00 to $957.00 and gave the company a “buy” rating in a report on Friday, June 7th. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research note on Wednesday, February 21st. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Bank of America raised their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $787.53.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the transaction, the insider now directly owns 98,554,195 shares in the company, valued at $79,730,343,755. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. In the last three months, insiders sold 567,826 shares of company stock valued at $475,376,178. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.